{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:11:51Z","timestamp":1793682711737,"version":"4.5.1"},"reference-count":161,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NHLBI R01 AR063070"],"award-info":[{"award-number":["NHLBI R01 AR063070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002492"],"award-info":[{"award-number":["KL2TR002492"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jid.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T13:53:54Z","timestamp":1712930034000},"page":"1943-1953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-2147","authenticated-orcid":false,"given":"Courtney","family":"Popp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-190X","authenticated-orcid":false,"given":"William","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7314-2550","authenticated-orcid":false,"given":"Cindy","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0957-4380","authenticated-orcid":false,"given":"Jakub","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-9964","authenticated-orcid":false,"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-911X","authenticated-orcid":false,"given":"Christen L.","family":"Ebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.03.008_bib1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jid.2024.03.008_bib2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, Phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jid.2024.03.008_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, Phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.03.008_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.03.008_bib5","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.jid.2017.07.002","article-title":"Pro-inflammatory chemokines and cytokines dominate the blister fluid molecular signature in patients with epidermolysis bullosa and affect leukocyte and stem cell migration","volume":"137","author":"Alexeev","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.podrm.2015.02.003","article-title":"Losartan: comprehensive profile","volume":"40","author":"Al-Majed","year":"2015","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"10.1016\/j.jid.2024.03.008_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1211505","article-title":"Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin","volume":"14","author":"Anderson-Crannage","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.03.008_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jid.2019.01.011","article-title":"Thrombospondin-1 is a major activator of TGF-\u03b2 signaling in recessive dystrophic epidermolysis bullosa fibroblasts","volume":"139","author":"Atanasova","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib9","first-page":"773","article-title":"Intravenous iron (III) hydroxide-sucrose complex for anaemia in epidermolysis bullosa","volume":"140","author":"Atherton","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/pde.14224","article-title":"Enteral iron absorption in patients with recessive dystrophic epidermolysis bullosa","volume":"37","author":"Augsburger","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molimm.2011.12.008","article-title":"IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2\/Stat6 signal transduction pathway: implication for atopic dermatitis","volume":"50","author":"Bao","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jid.2024.03.008_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2024.03.008_bib13","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.03.008_bib14","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114392","article-title":"Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7)","volume":"13","author":"Bernasconi","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2024.03.008_bib15","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","article-title":"QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study","volume":"141","author":"Bornert","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13023-022-02282-0","article-title":"Hand surgery and hand therapy clinical practice guideline for epidermolysis bullosa [published correction appears in Orphanet J Rare Dis 2022;17:438]","volume":"17","author":"Box","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","article-title":"The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers","volume":"15","author":"Bruckner","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ajg.2011.30","article-title":"Opioid-induced constipation: challenges and therapeutic opportunities","volume":"106","author":"Camilleri","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jid.2024.03.008_bib20","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1111\/jdv.17887","article-title":"A\u00a0case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab","volume":"36","author":"Caroppo","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.03.008_bib21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1172\/JCI115212","article-title":"Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma","volume":"87","author":"Castle","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2024.03.008_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.jid.5700645","article-title":"Epigallocatechin gallate\u2019s protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Changotade","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib23","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1111\/pde.13545","article-title":"Self-initiated use of topical cannabidiol oil for epidermolysis bullosa","volume":"35","author":"Chelliah","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/cge.14062","article-title":"The clinical efficacy and safety of anti-IgE therapy in recessive dystrophic epidermolysis bullosa","volume":"101","author":"Chen","year":"2022","journal-title":"Clin Genet"},{"key":"10.1016\/j.jid.2024.03.008_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/ced.14998","article-title":"Successful use of tofacitinib in epidermolysis bullosa pruriginosa","volume":"47","author":"Chen","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2019.09.014","article-title":"Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial","volume":"82","author":"Chiou","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2024.03.008_bib28","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jid.2017.02.239","article-title":"Quality of life in recessive dystrophic epidermolysis bullosa: the AltaVoice patient registry, 2012\u20132015","volume":"137","author":"Choi","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.matbio.2018.12.001","article-title":"Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa","volume":"81","author":"Cianfarani","year":"2019","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jid.2024.03.008_bib30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2024.03.008_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5045\/br.2013.48.1.10","article-title":"Role of hepcidin in the pathophysiology and diagnosis of anemia","volume":"48","author":"D\u2019Angelo","year":"2013","journal-title":"Blood Res"},{"key":"10.1016\/j.jid.2024.03.008_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/pde.12391","article-title":"Prevalence and characterization of pruritus in epidermolysis bullosa","volume":"32","author":"Danial","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/jdv.17671","article-title":"Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity","volume":"36","author":"Darbord","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.03.008_bib34","first-page":"97","article-title":"Fibrosis as a risk factor for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review","volume":"12","author":"de Azevedo","year":"2023","journal-title":"J\u00a0Pediatr Genet"},{"key":"10.1016\/j.jid.2024.03.008_bib35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jcyt.2023.01.015","article-title":"ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa [published correction appears in Cytotherapy 2023;25:1016]","volume":"25","author":"Dieter","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jid.2024.03.008_bib36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMc0906670","article-title":"Aprepitant as an antipruritic agent?","volume":"361","author":"Duval","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.03.008_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086147","article-title":"From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract","volume":"9","author":"Ebeling","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.03.008_bib38","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114864","article-title":"Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa","volume":"13","author":"Ebens","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2024.03.008_bib39","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bjd.17858","article-title":"Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts","volume":"181","author":"Ebens","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/09546634.2013.768327","article-title":"Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic epidermolysis bullosa, a randomized controlled trial","volume":"24","author":"El-Darouti","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.03.008_bib42","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","article-title":"Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: a global cross-sectional survey","volume":"85","author":"Eng","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib43","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/ijms17101625","article-title":"Autoimmunity and cytokine imbalance in inherited epidermolysis bullosa","volume":"17","author":"Esposito","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.03.008_bib44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","article-title":"Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa","volume":"17","author":"Feinstein","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib45","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/J.JHSB.2004.07.006","article-title":"Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National epidermolysis bullosa Registry, 1986-2002","volume":"30","author":"Fine","year":"2005","journal-title":"J\u00a0Hand Surg Br"},{"key":"10.1016\/j.jid.2024.03.008_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2230.2004.01428.x","article-title":"Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa","volume":"29","author":"Fine","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","article-title":"Cause-specific risks of childhood death in inherited epidermolysis bullosa","volume":"152","author":"Fine","year":"2008","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jid.2024.03.008_bib49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2015.04.015","article-title":"Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): results of a pilot trial","volume":"73","author":"Fine","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs","volume":"61","author":"Fine","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib51","doi-asserted-by":"crossref","first-page":"47156","DOI":"10.1074\/jbc.M308700200","article-title":"Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter","volume":"278","author":"Frank","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2024.03.008_bib52","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1365-2133.2008.08507.x","article-title":"Gastrointestinal complications of epidermolysis bullosa in children","volume":"158","author":"Freeman","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib53","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A\u00a0hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2024.03.008_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71794-1","article-title":"Cells from discarded dressings differentiate chronic from acute wounds in patients with epidermolysis bullosa","volume":"10","author":"Fuentes","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.03.008_bib55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","article-title":"Pain care for patients with epidermolysis bullosa: best care practice guidelines","volume":"12","author":"Goldschneider","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.jid.2024.03.008_bib56","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jid.2021.09.008","article-title":"Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa","volume":"142","author":"Gretzmeier","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/1153427-S0-000000000-00000","article-title":"A\u00a0case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis","volume":"11","author":"Gubinelli","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib58","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.03.008_bib59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In\u00a0vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2024.03.008_bib60","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature07039","article-title":"Wound repair and regeneration","volume":"453","author":"Gurtner","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.03.008_bib61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s13023-021-02062-2","article-title":"Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Guttmann-Gruber","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/biof.1587","article-title":"The role of interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration","volume":"46","author":"Harrell","year":"2020","journal-title":"BioFactors"},{"key":"10.1016\/j.jid.2024.03.008_bib63","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.matbio.2018.04.001","article-title":"Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone","volume":"71\u201372","author":"Has","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jid.2024.03.008_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4790810","article-title":"Aprepitant for the treatment of chronic refractory pruritus","volume":"2017","author":"He","year":"2017","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jid.2024.03.008_bib66","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-023-01935-z","article-title":"Birch bark extract: a review in epidermolysis bullosa","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2024.03.008_bib67","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","article-title":"Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa","volume":"30","author":"Hong","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/TCRM.S386923","article-title":"Innovations in the treatment of dystrophic epidermolysis bullosa (DEB): current landscape and prospects","volume":"19","author":"Hou","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jid.2024.03.008_bib69","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ndt\/gfg159","article-title":"The thrombospondin 1-TGF-beta axis in fibrotic renal disease","volume":"18","author":"Hugo","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jid.2024.03.008_bib70","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex\u00a0vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jid.2024.03.008_bib71","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jid.2024.03.008_bib72","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.3390\/cancers13195019","article-title":"Targeting ovarian carcinoma with TSP-1:CD47 antagonist TAX2 activates anti-tumor immunity","volume":"13","author":"Jeanne","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2024.03.008_bib73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis bullosa pruriginosa treated with baricitinib","volume":"157","author":"Jiang","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dth.12113","article-title":"Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant","volume":"27","author":"Jim\u00e9nez Gallo","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/bjd\/ljac001","article-title":"Efficacy and safety of oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study","volume":"188","author":"Kern","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib76","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-2781","article-title":"Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand","volume":"98","author":"Kim","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2024.03.008_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2024.03.008_bib78","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0168-8278(03)00377-5","article-title":"A\u00a0blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in\u00a0vivo","volume":"39","author":"Kondou","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jid.2024.03.008_bib79","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1525-1470.2006.00314.x","article-title":"Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa","volume":"23","author":"Kuo","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib80","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2014.185","article-title":"Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity","volume":"134","author":"K\u00fcttner","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib81","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/msb.2013.17","article-title":"Global remodelling of cellular microenvironment due to loss of collagen VII","volume":"9","author":"K\u00fcttner","year":"2013","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.jid.2024.03.008_bib82","article-title":"Psoriasis patients treated with methotrexate have an increased risk of nonmelanoma skin cancer: a systematic review and meta-analysis","volume":"15","author":"Lang Houser","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.03.008_bib83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2010.01.047","article-title":"The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial","volume":"66","author":"Lara-Corrales","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib84","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1055\/s-2006-951723","article-title":"Physical, chemical and pharmacological characterization of a new oleogel-forming triterpene extract from the outer bark of birch (betulae cortex)","volume":"72","author":"Laszczyk","year":"2006","journal-title":"Planta Med"},{"key":"10.1016\/j.jid.2024.03.008_bib85","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-beta signaling and the fibrotic response","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.jid.2024.03.008_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143606","article-title":"Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2024.03.008_bib87","first-page":"1","article-title":"Why do wounds itch?","volume":"30","author":"Lerner","year":"2018","journal-title":"Wounds"},{"key":"10.1016\/j.jid.2024.03.008_bib88","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3892\/etm.2016.3640","article-title":"LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-\u03b21 signaling activity following subarachnoid hemorrhage in rats","volume":"12","author":"Liao","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jid.2024.03.008_bib89","first-page":"129","article-title":"Oleogel-S10 to accelerate healing of donor sites: monocentric results of phase Iii clinical trial","volume":"59","author":"Lipov\u00fd","year":"2018","journal-title":"Acta Chir Plast"},{"key":"10.1016\/j.jid.2024.03.008_bib90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-022-02448-w","article-title":"Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa","volume":"18","author":"Liy-Wong","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2024.03.008_bib92","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/jid.2014.500","article-title":"Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa","volume":"135","author":"Mack","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib93","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv293","article-title":"Suppression of TGF\u03b2 and angiogenesis by type VII collagen in cutaneous SCC","volume":"108","author":"Martins","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jid.2024.03.008_bib94","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/ijms23031732","article-title":"5\u2019RNA trans-splicing repair of COL7A1 mutant transcripts in epidermolysis bullosa","volume":"23","author":"Mayr","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.03.008_bib95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2133.1994.tb13109.x","article-title":"Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features","volume":"130","author":"McGrath","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2010.01.004","article-title":"Infection and colonization in epidermolysis bullosa","volume":"28","author":"Mellerio","year":"2010","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jid.2024.03.008_bib97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13023-023-02817-z","article-title":"Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study","volume":"18","author":"Mellerio","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-15-1348","article-title":"Injury-driven stiffening of the dermis expedites skin carcinoma progression","volume":"76","author":"Mittapalli","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2024.03.008_bib99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ad.2019.11.002","article-title":"Innovation in atopic dermatitis: from pathogenesis to treatment","volume":"111","author":"Munera-Campos","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.jid.2024.03.008_bib100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hgtb.2012.180","article-title":"A\u00a0reporter-based screen to identify potent 3\u2019 trans-splicing molecules for endogenous RNA repair","volume":"24","author":"Murauer","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jid.2024.03.008_bib101","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jid.2024.03.008_bib102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1744-9987.13699","article-title":"Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: a phase 3 open-label study in Japan","volume":"26","author":"Nangaku","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.03.008_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100191","article-title":"Cytosine deaminase base editing to restore COL7A1 in dystrophic epidermolysis bullosa human: murine skin model","volume":"3","author":"Naso","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.jid.2024.03.008_bib104","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-11-2996","article-title":"Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa","volume":"72","author":"Ng","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2024.03.008_bib105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00043426-200001000-00010","article-title":"Treatment of iron deficiency anemia and associated protein-losing enteropathy in children","volume":"22","author":"Nickerson","year":"2000","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jid.2024.03.008_bib106","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/bioengineering10040422","article-title":"Stem cell therapies for epidermolysis bullosa treatment","volume":"10","author":"Niti","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.jid.2024.03.008_bib107","doi-asserted-by":"crossref","first-page":"E705","DOI":"10.1073\/pnas.1709111115","article-title":"Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa","volume":"115","author":"Nystr\u00f6m","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jid.2024.03.008_bib108","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2024.03.008_bib109","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2024.03.008_bib110","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1093\/hmg\/ddu102","article-title":"Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-\u03b2 signalling in modifying disease severity","volume":"23","author":"Odorisio","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jid.2024.03.008_bib111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/exd.14481","article-title":"Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing","volume":"31","author":"Onoufriadis","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib112","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","article-title":"Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs","volume":"140","author":"Osborn","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib113","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib114","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.19496","article-title":"Prevalence, pathophysiology and management of itch in epidermolysis bullosa","volume":"184","author":"Papanikolaou","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib115","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1517\/14656566.4.12.2279","article-title":"Aprepitant--a novel NK1-receptor antagonist","volume":"4","author":"Patel","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jid.2024.03.008_bib116","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.ASW.0000431203.64591.2f","article-title":"Characteristics of chronic wounds that itch","volume":"26","author":"Paul","year":"2013","journal-title":"Adv Skin Wound Care"},{"key":"10.1016\/j.jid.2024.03.008_bib117","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ymthe.2020.05.017","article-title":"Exposed CendR domain in homing peptide yields skin-targeted therapeutic in epidermolysis bullosa","volume":"28","author":"Pemmari","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib118","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa","volume":"132","author":"Pendaries","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib119","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jdermsci.2020.10.009","article-title":"Aberrant recruitment of leukocytes defines poor wound healing in patients with recessive dystrophic epidermolysis bullosa","volume":"100","author":"Phillips","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2024.03.008_bib121","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of methotrexate and risk of skin cancer: a nationwide case-control study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2024.03.008_bib122","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2012.01.016","article-title":"A\u00a0consensus approach to wound care in epidermolysis bullosa","volume":"67","author":"Pope","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15515","article-title":"Losartan treatment improves recessive dystrophic epidermolysis bullosa: a case series","volume":"35","author":"Pourani","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib125","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/bjd.18475","article-title":"Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study","volume":"182","author":"Reimer","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib126","doi-asserted-by":"crossref","first-page":"13586","DOI":"10.1074\/jbc.274.19.13586","article-title":"The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta","volume":"274","author":"Ribeiro","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2024.03.008_bib127","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/stem.3356","article-title":"ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment","volume":"39","author":"Riedl","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.jid.2024.03.008_bib128","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jcyt.2021.06.004","article-title":"Mesenchymal stromal cells in wound healing applications: role of the secretome, targeted delivery and impact on recessive dystrophic epidermolysis bullosa treatment","volume":"23","author":"Riedl","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jid.2024.03.008_bib129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ad.2022.05.045","article-title":"Successful control of recalcitrant pruritus in epidermolysis bullosa pruriginosa with dupilumab","volume":"115","author":"Roque Quintana","year":"2024","journal-title":"Actas Dermo Sifiliogr"},{"key":"10.1016\/j.jid.2024.03.008_bib130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/a-0850-0224","article-title":"The wound healing properties of betulin from birch bark from bench to bedside","volume":"85","author":"Scheffler","year":"2019","journal-title":"Planta Med"},{"key":"10.1016\/j.jid.2024.03.008_bib131","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Sch\u00f6del","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jid.2024.03.008_bib132","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.17341","article-title":"Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases","volume":"180","author":"Schr\u00e4der","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277512","article-title":"The C4EB study-Transvamix (10% THC \/ 5% CBD) to treat chronic pain in epidermolysis bullosa: a protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study","volume":"17","author":"Schr\u00e4der","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.03.008_bib134","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-021-02010-0","article-title":"Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study","volume":"16","author":"Schr\u00e4der","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib135","first-page":"5836s","article-title":"Identifying epidermolysis bullosa patient needs and perceived treatment benefits: an explorative study using the patient benefit index","volume":"10","author":"Schr\u00e4der","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jid.2024.03.008_bib136","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2827","article-title":"Pain quality assessment scale for epidermolysis bullosa","volume":"98","author":"Schr\u00e4der","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2024.03.008_bib137","article-title":"Mechanism of oleogel-S10: a triterpene preparation for the treatment of epidermolysis bullosa","volume":"32","author":"Schwieger-Briel","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib138","series-title":"StatPearls","article-title":"Cannabinoids","author":"Sheikh","year":"2023"},{"key":"10.1016\/j.jid.2024.03.008_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24184-8","article-title":"ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation","volume":"12","author":"Sheriff","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.03.008_bib140","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jid.2021.10.026","article-title":"Angiogenin released from ABCB5+ stromal precursors improves healing of diabetic wounds by promoting angiogenesis","volume":"142","author":"Singh","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib141","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2024.03.008_bib142","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","article-title":"Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa","volume":"17","author":"So","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib143","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A\u00a0systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2024.03.008_bib144","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/pde.15239","article-title":"Iron status and burden of anemia in children with recessive dystrophic epidermolysis bullosa","volume":"40","author":"Tarango","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib145","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jaad.2011.01.016","article-title":"Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues","volume":"66","author":"Torres","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib146","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A\u00a024-week anemia correction study of daprodustat in Japanese dialysis patients","volume":"24","author":"Tsubakihara","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jid.2024.03.008_bib147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF00370713","article-title":"Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene","volume":"287","author":"Uitto","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2024.03.008_bib148","doi-asserted-by":"crossref","first-page":"501","DOI":"10.12968\/jowc.2013.22.9.501","article-title":"Wound pruritus: prevalence, aetiology and treatment","volume":"22","author":"Upton","year":"2013","journal-title":"J\u00a0Wound Care"},{"key":"10.1016\/j.jid.2024.03.008_bib149","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/stem.3022","article-title":"Newly defined ATP-binding cassette subfamily B Member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist","volume":"37","author":"Vander Beken","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.jid.2024.03.008_bib150","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/brain\/awx069","article-title":"Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy","volume":"140","author":"von Bischhoffshausen","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jid.2024.03.008_bib151","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9610(99)80340-7","article-title":"The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen","volume":"170","author":"Wang","year":"1995","journal-title":"Am J Surg"},{"key":"10.1016\/j.jid.2024.03.008_bib152","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15130","article-title":"Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: a case report","volume":"34","author":"Wang","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.03.008_bib153","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/acs.jnatprod.6b00027","article-title":"Influence of birch bark triterpenes on keratinocytes and fibroblasts from diabetic and nondiabetic donors","volume":"79","author":"Wardecki","year":"2016","journal-title":"J\u00a0Nat Prod"},{"key":"10.1016\/j.jid.2024.03.008_bib154","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/jid.2009.248","article-title":"Triterpenes promote keratinocyte differentiation in\u00a0vitro, ex\u00a0vivo and in\u00a0vivo: a role for the transient receptor potential canonical (subtype) 6","volume":"130","author":"Woelfle","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.03.008_bib155","article-title":"Losartan attenuates myocardial endothelial-to-mesenchymal transition in spontaneous hypertensive rats via inhibiting TGF-\u03b2\/Smad signaling","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.03.008_bib156","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12272-010-0213-6","article-title":"LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction","volume":"33","author":"Xie","year":"2010","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jid.2024.03.008_bib157","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.03.008_bib158","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.03.008_bib159","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/DERM.0000000000000954","article-title":"Dystrophic epidermolysis bullosa pruriginosa: successfully treated with dupilumab","volume":"34","author":"Yu","year":"2023","journal-title":"Dermatitis"},{"key":"10.1016\/j.jid.2024.03.008_bib160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s40001-023-01465-0","article-title":"Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study","volume":"28","author":"Zhang","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jid.2024.03.008_bib161","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47635-2","article-title":"Thrombospondin1 antagonist peptide treatment attenuates obesity-associated chronic inflammation and metabolic disorders in a diet-induced obese mouse model","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci Rep"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:54:48Z","timestamp":1762206888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":161,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0022202X24001982"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.03.008","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}